BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18996907)

  • 1. Risk reducing mastectomy: outcomes in 10 European centres.
    Evans DG; Baildam AD; Anderson E; Brain A; Shenton A; Vasen HF; Eccles D; Lucassen A; Pichert G; Hamed H; Moller P; Maehle L; Morrison PJ; Stoppat-Lyonnet D; Gregory H; Smyth E; Niederacher D; Nestle-Krämling C; Campbell J; Hopwood P; Lalloo F; Howell A
    J Med Genet; 2009 Apr; 46(4):254-8. PubMed ID: 18996907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice.
    Bancroft EK; Locke I; Ardern-Jones A; D'Mello L; McReynolds K; Lennard F; Barbachano Y; Barwell J; Walker L; Mitchell G; Dorkins H; Cummings C; Paterson J; Kote-Jarai Z; Mitra A; Jhavar S; Thomas S; Houlston R; Shanley S; Eeles RA
    J Med Genet; 2010 Jul; 47(7):486-91. PubMed ID: 20472659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
    Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
    Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
    Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
    Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution.
    Mislowsky A; Domchek S; Stroede C; Bergey MR; Sonnad SS; Wu L; Tchou J
    Ann Surg Oncol; 2011 Mar; 18(3):745-51. PubMed ID: 20972632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
    Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
    Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
    Fatouros M; Baltoyiannis G; Roukos DH
    Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer after bilateral risk-reducing mastectomy.
    Skytte AB; Crüger D; Gerster M; Laenkholm AV; Lang C; Brøndum-Nielsen K; Andersen MK; Sunde L; Kølvraa S; Gerdes AM
    Clin Genet; 2011 May; 79(5):431-7. PubMed ID: 21199491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of preventive measures among BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
    Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preventive surgical prcedures for inherited risk of breast cancer].
    Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
    Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
    Hartmann LC; Schaid DJ; Woods JE; Crotty TP; Myers JL; Arnold PG; Petty PM; Sellers TA; Johnson JL; McDonnell SK; Frost MH; Jenkins RB
    N Engl J Med; 1999 Jan; 340(2):77-84. PubMed ID: 9887158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilisation of prophylactic mastectomy in 10 European centres.
    Evans DG; Anderson E; Lalloo F; Vasen H; Beckmann M; Eccles D; Hodgson S; Møller P; Chang-Claude J; Morrison P; Stoppa-Lyonnet D; Steel M; Haites N
    Dis Markers; 1999 Oct; 15(1-3):148-51. PubMed ID: 10595270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer.
    Antill Y; Reynolds J; Young MA; Kirk J; Tucker K; Bogtstra T; Wong S; Dudding T; Di Iulio J; Phillips KA
    Eur J Cancer; 2006 Mar; 42(5):621-8. PubMed ID: 16434187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.
    Fryzek JP; Ye W; Nyrén O; Tarone RE; Lipworth L; McLaughlin JK
    Breast Cancer Res Treat; 2006 May; 97(2):131-4. PubMed ID: 16328720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
    Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
    Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.